Blueprint Medicines says partner Genentech withdraws use of Gavreto for thyroid cancer

In this article:

June 30 (Reuters) - Blueprint Medicines said on Friday its partner Genentech Inc has withdrawn use of its cancer drug Gavreto for treating a type of thyroid cancer in patients aged 12 years and above. (Reporting by Raghav Mahobe in Bengaluru; Editing by Dhanya Ann Thoppil)

Advertisement